SWSteffen Wahler

Steffen Wahler

*This is an algorithmically generated author record based on publicly available information.

Steffen Wahler has a total of 182 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative Pharmacokinetics of Trientine Dihydrochloride Capsules: A Randomized, Open-Label, Reference-Controlled, Two-Period Crossover Study in Healthy Volunteers

    by Christian J. Hartmann, Frank Tacke, Isabelle Mohr, Michael Praktiknjo, Martin Jankofsky, Steffen Wahler, Karl Heinz Weiss

  • Verbesserungsbedarf in der Versorgung von Patienten/-innen mit Clostridioides-difficile-lnfektionen (CDI) – Experten/-innenmeinung im internationalen Vergleich

    by Maria J. G. T. Vehreschild, Stefan Schreiber, Lutz von Müller, Hans-Jörg Epple, Carolin Manthey, Jun Oh, Thomas Weinke, Steffen Wahler, Andreas Stallmach

    Zusammenfassung: Einführung Die Clostridioides-difficile-Infektion (CDI) ist mit einer hohen Morbidität und Mortalität assoziiert. Auch wenn ihre Inzidenz in den letzten Jahren in Deutschland rückläufig ist, kann die individuelle Infektion trotz therapeutischen Fortschritts eine medizinische Herausforderung darstellen. Hier soll geklärt werden, welche Lücken verantwortliche Behandler/-innen in der Versorgung und in der Evidenzlage als besonders gravierend ansehen. Methoden In einem moderierten Workshop von in Deutschland tätigen CDI-Experten/-innen, wurden als relevant eingeschätzte Fragestellungen ermittelt. Eine bereits in fünf anderen Ländern (Australien, Frankreich, Großbritannien, Kanada und Italien) durchgeführte Befragung wurde ergänzend angepasst und von 27 Behandlern/-innen bearbeitet. Bei der Auswertung wurden die als besonders wichtig empfundenen Themen herausgearbeitet, die Aussagen der Fachgruppen verglichen und Meinungsänderungen berücksichtigt. Ergebnisse 27 vollständig ausgefüllte Fragebögen wurden ausgewertet. Verbesserungsbedarf wurde vorrangig bei der Verhinderung von CDI-Rezidiven (74,1%), sowie Therapie der Rezidive (55,6%) gesehen. Evidenzdefizite wurden bei der Behandlung von Rezidiven (55,6%) und der Identifikation der Risikofaktoren für Rezidive konstatiert (48,1%). Die Verbesserung der Versorgung mittels fäkalem Mikrobiota-Transfer (FMT) nannten 70,4%. Bei Leitlinien wurde mehr Klarheit (48,1%) und regelmäßigere Aktualisierung (40,7%) gewünscht. Für Patienten/-innen wurden bessere Aufklärung der über angemessenen Antibiotikaeinsatz (52,0%) und Wahlmöglichkeiten der FMT angestrebt (48,1%). Zusammenfassung Bei der Frage nach Verbesserungsbedarf in der Versorgung und Evidenzlücken bei der Behandlung von Patienten/-innen mit CDI ist die nationale Experten/-innensicht in Deutschland, wie auch die internationale Einschätzung ähnlich: Im Zentrum steht die Prävention und Therapie der rezidivierenden CDI. Die Problematik des Zugangs zum FMT ist eine deutsche Besonderheit, die verbesserungspflichtig erscheint.


  • Fäkaler Mikrobiota-Transfer (FMT) in Deutschland – Status und Perspektive

    by Andreas Stallmach, Lutz von Müller, Martin Storr, Alexander Link, Peter C. Konturek, Philipp Christoph Solbach, Karl Heinz Weiss, Steffen Wahler, Maria J. G. T. Vehreschild

    Zusammenfassung: Einführung Der Fäkale Mikrobiota-Transfer (FMT) ist eine Behandlung zur Modulation der gastrointestinalen Mikrobiota. Der Einsatz bei rezidivierender Clostridioides-difficile-Infektion (rCDI) ist europaweit etabliert und wird in nationalen und internationalen Leitlinien empfohlen. Der FMT ist in Deutschland im Fallpauschalensystem der Krankenhäuser kodierfähig. Eine auf dieser Kodierung basierende umfassende Erhebung zur Häufigkeit des Einsatzes fehlt bislang. Material und Methodik Berichte des Instituts für das Entgeltsystem im Krankenhaus (InEK), des Statistischen Bundesamtes (DESTATIS) und Qualitätsberichte der Krankenhäuser 2015–2021 wurden auf FMT-Kodierung hin untersucht und im Rahmen einer strukturierten Expertenkonsultation bewertet. Ergebnisse Zwischen 2015 und 2021 wurden von 175 Krankenhäusern 1.645 FMT-Verfahren kodiert. Von 2016 bis 2018 waren dies jährlich im Median 293 (274–313) FMT, gefolgt von einem konstanten Rückgang in den folgenden Jahren auf 119 FMT im Jahr 2021. Patienten/-innen mit FMT waren zu 57,7% weiblich, im Median 74 Jahre alt und der FMT wurde zu 72,2% koloskopisch appliziert. Bei 86,8 % der Fälle wurde eine CDI als Hauptdiagnose genannt, gefolgt von 7,6% eine Colitis ulcerosa. Diskussion In Deutschland wird der FMT seltener eingesetzt als im europäischen Vergleich. Eine Anwendungshürde ist die behördliche Einordnung des FMT als nicht zugelassenes Arzneimittel, die zu erheblich höherem Aufwand bei Herstellung und Verabreichung führt und eine Erstattung erschwert. Die Europäische Kommission hat kürzlich eine Verordnung vorgeschlagen, den FMT als Transplantation einzuordnen. Dies könnte die regulatorische Situation des FMT in Deutschland perspektivisch verändern und so zu einem flächendeckenden Angebot eines in Leitlinien empfohlenen Therapieverfahrens beitragen.


  • Trends in the epidemiology of Clostridioides difficile infection in Germany

    by Maria Johanna Gobertina Tetuanui Vehreschild, Stefan Schreiber, Lutz von Müller, Hans-Jörg Epple, Thomas Weinke, Carolin Manthey, Jun Oh, Steffen Wahler, Andreas Stallmach

    Purposes Despite reports of a declining incidence over the last decade, Clostridioides difficile infection (CDI) is still considered the most important healthcare-associated causes of diarrhea worldwide. In Germany, several measures have been taken to observe, report, and influence this development. This report aims to analyze the development of hospital coding for CDI in Germany over the last decade and to use it to estimate the public health burden caused by CDI. Methods Reports from the Institute for Hospital Remuneration Systems, German Federal Statistical Office (DESTATIS), the Robert-Koch-Institute (RKI), Saxonian authorities and hospital quality reports during 2010–2021 were examined for CDI coding and assessed in a structured expert consultation. Analysis was performed using 2019 versions of Microsoft Excel® and Microsoft Access®. Results Peaks of 32,203 cases with a primary diagnosis (PD) of CDI and 78,648 cases with a secondary diagnosis (SD) of CDI were observed in 2015. The number of cases had decreased to 15,412 PD cases (− 52.1%) and 40,188 SD cases (− 48.9%) by 2021. These results were paralleled by a similar decline in notifiable severe cases. However, average duration of hospitalization of the cases remained constant during this period. Conclusions Hospital coding of CDI and notification to authorities has approximately halved from 2015 to 2021. Potential influential factors include hospital hygiene campaigns, implementation of antibiotic stewardship programs, social distancing due to the COVID-19 pandemic, and a decrease in more pathogenic subtypes of bacteria. Further research is necessary to validate the multiple possible drivers for this development.


  • Open Access

    Clinical utility of the acoustic detection of coronary stenosis as an early rule-out criterion: a blinded, prospective, monocentric study versus standard care

    by Ralf Birkemeyer, Jane Wittenberg, Alfred Müller, Steffen Wahler

    Background: The CADScor®System is a noninvasive and radiation-free technology that searches for stenosis induced by turbulent coronary blood flow. A CADSscore represents the acoustic detection results of coronary stenoses. We assessed consecutive patients with stable symptoms without known coronary artery disease (CAD) to define a low risk for obstructive CAD based on a low CAD score than a standard approach of clinical assessment using noninvasive and invasive diagnostic measurements. Methods: Overall, 214 consecutive patients aged ˃40 years in a German cardiological outpatient unit were included. Patients underwent an initial clinical assessment, a double-blinded CAD score, standard examinations, and a national guidance-based diagnostic cascade. They underwent a 6-month telephone follow-up to capture future CAD events. A CAD score of ≤20 was defined as low risk. Results: Overall, 196 patients completed the planned diagnostic workup after their initial visit, and 187 had a valid CAD score. All 196 patients underwent an electrocardiogram (ECG) and echocardiography, and 178 patients underwent a stress ECG. According to the initial standard evaluation, 41 patients were considered to be low-risk without further diagnosis. A CAD score of ≤20 was found in 51 patients. According to clinical standards, 85 and 77 patients underwent noninvasive testing and invasive angiography, respectively. The obstructive CAD was invasively diagnosed in 25 patients, of whom 4 had a CAD score of ≤20. No additional CAD was detected at the 6-month follow-up. Overall, 41 of the 165 noninvasive and invasive diagnostic procedures could have been avoided with a CAD score of ≤20 as the exclusion criterion for further diagnosis after the standard initial diagnosis. Furthermore, 10 of the 52 invasive procedures without evidence of obstructive CAD could have been prevented. Conclusions: The obstructive CAD was confirmed in 12.8% of patients with stable symptoms and suspected CAD. Therefore, advanced noninvasive testing was mainly used for further CAD exclusion. The diagnostic yield of invasive angiography was low, and approximately a quarter of further diagnostic procedures could have been avoided with the CAD score, which showed an acceptable false-negative rate compared with the standard diagnostic tools. Trial registration: Deutsches Register Klinischer Studien (DRKS): DRKS00016986 (22/03/2019)

  • Open Access

    Cost-effectiveness of a photopethysmographic procedure for screening for atrial fibrillation in 6 European countries

    by Steffen Wahler, Ralf Birkemeyer, Dimitrios Alexopoulos, Zbigniew Siudak, Alfred Müller, Johann-Matthias von der Schulenburg

    Background: Strokes cause an estimated annual health care burden of 170 billion euros across Europe. Atrial fibrillation is one of the major risk factors for stroke and increases the individual risk 4.2-fold. But prevention with anticoagulants may reduce this risk by 70%. Screening methods are employed to detect previously undetected atrial fibrillation. Screening studies in various European countries show a high degree of undetected atrial fibrillation. This study aims to assess the cost-effectiveness of systematic screening with a smartphone application, named Preventicus Heartbeats. It is a hands-on screening tool for use on smartphone to diagnose AF with high sensitivity and specificity. Methods: A previously published model for calculating screening cost-effectiveness was extended to 6 European countries covering a wide range in terms of treatment costs and epidemiologic parameters. Results: The use of screening lowers the cost per case in countries with comparatively high levels of health care costs (Switzerland: -€75; UK: -€7). Moderate higher costs per case were observed in 4 countries (Greece: €6; Netherlands: €15). Low levels of health care costs result in less or no potential for further cost reduction (Poland: €20; Serbia: €33). In all countries considered, the model showed an increase in effectiveness measures both in the number of strokes avoided and the quality adjusted life years. The number of strokes avoided per 1000 participants ranged from 2.52 (Switzerland) to 4.44 (Poland). Quality-adjusted life-years per case gained from screening ranged from 0.0105 (Switzerland) to 0.0187 (Poland). The screening procedure dominated in two countries (Switzerland, UK). For the remaining countries, the incremental cost effectiveness ratio ranged from €489/QALY (Greece) to €2548/QALY (Serbia). Conclusion: The model results showed a strong dependence of the results on the country-specific costs for stroke treatment. The use of the investigated screening method is close to cost-neutral or cost-reducing in the Western European countries and Greece. In countries with low price levels, higher cost increases due to AF screening are to be expected. Lower costs of anticoagulation, which are expected due to the upcoming patent expiry of direct anticoagulants, have a positive effect on the cost result.


  • Open Access

    Adjuvant treatment of high-risk melanoma – cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors

    by Steffen Wahler, Alfred Müller, Sabine Fuchs, Johann-Matthias von der Schulenburg

    Introduction: Until recently, adjuvant treatment options for higher stage resectable cutaneous melanoma were limited. Two studies with a similar set-up, published 2017, led to registration of targeted therapy for BRAF-mutated melanoma with dabrafenib and trametinib as well as of the immunotherapy with nivolumab irrespective of BRAF-mutation status. Both options have been positively assessed in Germany since 2019 for the adjuvant treatment of BRAF-V600 mutated melanoma. This study evaluates the cost-effectiveness of both treatment alternatives (dabrafenib/trametinib and nivolumab) against observation as a comparative therapy from the perspective of German statutory health funds. Methods: Partitioned survival analysis based on published survival curves for the investigated treatment options was used for a cohort model for the health states relapse free survival, progression, and death. The partitioned survival analysis approach was based on the survival curves published for the key studies Combi AD and Checkmate-238. The modelling was performed for the remaining lifetime for a cohort with starting age of 50 years. For extrapolation of the survival curves, convergence to general population mortality rates was assumed in the long term. Within the progression state, a Markov model uses three levels of progressions (locoregional, distant metastases with 1st and 2nd line treatment). Lifetime treatment costs were calculated using the German statutory health fund reimbursement scheme. Quality adjusted life years (QALYs) associated to the health states were adopted from previously published utilities based on the Combi AD study. Results: The treatment with dabrafenib/trametinib yielded an increase in quality adjusted life years of 2.28 QALY at an incremental lifetime cost of 86.1 T€. The incremental cost effectiveness ratio of dabrafenib/trametinib and nivolumab was comparable with 37.8 T€/QALY and 30.0 T€/QALY, respectively. Several sensitivity analyses proved the result to be insensitive. General model parameters like discount rate and length of the time horizon had stronger influence. For nivolumab, the model showed lower discounted lifetime costs (118.1 T€) compared to dabrafenib/trametinib [155.1 T€], associated with a lower gain in QALYs (1.64 years) compared to observation. Conclusion: Both dabrafenib/trametinib and nivolumab turned out to be cost effective within internationally accepted Incremental Cost Effectiveness Ratio (ICER) thresholds with comparable cost effectiveness ratios.


  • Open Access

    The Ecological Footprint of COVID-19 mRNA Vaccines: Estimating Greenhouse Gas Emissions in Germany

    by Peter Kurzweil, Alfred Müller, Steffen Wahler

    Compared to the medical, economic and social implications of COVID-19 vaccinations, little attention has been paid to the ecological balance to date. This study is an attempt to estimate the environmental impact of two mRNA vaccines in terms of CO2 equivalents with respect to their different freezing strategies and supply chain organization. Although it is impossible to accurately calculate the actual environmental impact of the new biochemical synthesis technology, it becomes apparent that transport accounts for up to 99% of the total carbon footprint. The emissions for air freight, road transportation and last-mile delivery are nearly as 19 times the emissions generated from ultra-deep freeze technologies, the production of dry ice, glass and medical polymers for packaging. The carbon footprint of a single mRNA vaccine dose injected into a patient is about 0.01 to 0.2 kg CO2 equivalents, depending on the cooling technology and the logistic routes to the vaccination sites in Germany.


  • Open Access

    Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany

    by S Wahler, A Müller, C Koll, P Seyed-Abbaszadeh, Jm Von Der Schulenburg

    Background: Adjuvant treatment options have become the standard therapy for stage III and IV resectable cutaneous melanoma. Two recent studies led to the registration of dabrafenib and trametinib as targeted therapies for BRAF-mutated melanoma, and of immunotherapy with nivolumab irrespective of BRAF-mutation status. Both therapies have different spectrums of adverse events.


  • The rising incidence of acquired haemophilia A in Germany

    by Andreas Tiede, Steffen Wahler